University Hospital, Rouen
The main objective of this prospective multisite trial is to study the evolution of TMA (thrombotic microangiopathy) induced by gemcitabin and treated by eculizumab.
Thrombotic Microangiopathies
Eculizumab administration
Phase 3
Study Type : | Interventional |
Estimated Enrollment : | 10 participants |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies |
Actual Study Start Date : | March 2023 |
Estimated Primary Completion Date : | September 2025 |
Estimated Study Completion Date : | September 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Patient with Thrombotic microangiopathies induced by gemcitabine Patient with Thrombotic microangiopathies induced by gemcitabine will be treat with Eculizumab |
Drug: Eculizumab administration |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Amiens University Hospital
Amiens, France,
Not yet recruiting
Rouen University Hospital
Rouen, France,